Company profile
Panbela Therapeutics, Inc.
OTC: PBLA · Healthcare · Biotechnology
#846 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 19GM —SS 24
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), 3-yr revenue growth · ↓ market scale, disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$25.3M
Employees
8
as of 2026-08-28
Market cap
$485
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.4M$1.4M2014
Net income-$25.3M-$25.3M2023
Operating income-$25.6M-$25.6M2023
Total assets$11.8M$11.8M2023
Liabilities$16.5M$16.5M2023
Equity-$4.7M-$4.7M2023
Revenue trend
FY2012 – FY2014 · USD
FY12
FY12
FY13
FY14
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Panbela Therapeutics, Inc.’s revenue?
Panbela Therapeutics, Inc. booked $1.4M in FY2014 revenue, growing 39% year over year — faster than most Healthcare companies we track, at a -1861.7% net margin.
Peers · Healthcare
Affymax, Inc.——CannaPharmaRX, Inc.38DOneMedNet Corporation26DElectromedical Technologies, Inc.——Global Roundtable Corporation——Inhibrx Biosciences Inc.28DNeighbors
Carver →Key facts
CEOJennifer K. Simpson
SectorHealthcare
IndustryBiotechnology
HeadquartersWaconia, MN
ExchangeOTC: PBLA
Employees8
IPO date2017-01-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.